EGFR and non-small cell lung carcinoma: Targeting this pathway with pH‐responsive F127ZIF‐8AB680, nanoparticles to carry a CD73 inhibitor, effectively mitigated adenosine production within the acidic TME, thereby enhancing DC functionality and CD8+ T cell responses, highlighting a promising therapeutic approach for overcoming the immunotherapy resistance in EGFR‐mutant NSCLC.